Wall Street analysts’ estimates
Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018. The earnings per share are expected to be $4.66 in 2019. Analysts estimate the net income margin to increase to 27.3% during 2019 as compared to 18.9% during 2018.
The above chart compares changes in analysts’ recommendations for Abiomed since January 2018.
Abiomed estimates revenues to be between $755 million and $770 million during 2019, a 27% to 30% increase in revenues as compared to 2018. The operating margin is expected to be in the range of 28% to 30% in 2019.
Abiomed’s stock price has increased by nearly 172.3% in the last 12 months and nearly 119.5% in 2018 year-to-date. Analysts estimate the stock might increase by 9.2% over the next 12 months. Wall Street analysts have a 12-month target price of $449.22 per share as compared to the last price of $411.36 per share as of September 4.
As of September 5, 11 analysts are tracking Abiomed. Of these, five analysts recommend a “strong buy,” four analysts recommend a “buy,” and two analysts recommend a “hold.” None of the analysts recommend a “sell.” The consensus rating for Abiomed stands at 1.73, which represents a “strong buy” for long-term growth investors as well as momentum investors. Changes in analysts’ estimates and recommendations are based on changing trends in stock prices and the performance of the company.